MX2021000894A - Dosificacion optimizada de diaminofenotiazinas en poblaciones. - Google Patents

Dosificacion optimizada de diaminofenotiazinas en poblaciones.

Info

Publication number
MX2021000894A
MX2021000894A MX2021000894A MX2021000894A MX2021000894A MX 2021000894 A MX2021000894 A MX 2021000894A MX 2021000894 A MX2021000894 A MX 2021000894A MX 2021000894 A MX2021000894 A MX 2021000894A MX 2021000894 A MX2021000894 A MX 2021000894A
Authority
MX
Mexico
Prior art keywords
diaminophenothiazines
populations
lmt
optimised
dosage
Prior art date
Application number
MX2021000894A
Other languages
English (en)
Inventor
Claude Michel Wischik
Björn Olaf Schelter
Helen Christine Shiells
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1812193.9A external-priority patent/GB201812193D0/en
Priority claimed from GBGB1909458.0A external-priority patent/GB201909458D0/en
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of MX2021000894A publication Critical patent/MX2021000894A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/29—Mineral substances, e.g. mineral oils or clays
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a regímenes de dosificación novedosos para compuestos de Leuco-Metiltioninio los cuales maximizan la proporción de sujetos en los cuales la concentración de MT excederá las concentraciones en las cuales la eficacia terapéutica con relación al tratamiento de trastornos neurodegenerativos tales como enfermedad de Alzheimer y demencias frontotemporal se pueden lograr, mientras mantienen un perfil clínico deseable. También se proporcionan unidades de dosificación que contienen LMT y otras composiciones.
MX2021000894A 2018-07-26 2019-07-18 Dosificacion optimizada de diaminofenotiazinas en poblaciones. MX2021000894A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1812193.9A GB201812193D0 (en) 2018-07-26 2018-07-26 Optimised dosage of diaminophenothiazines in populations
GBGB1909458.0A GB201909458D0 (en) 2019-07-01 2019-07-01 Optimised dosage of diaminophenothiazines in populations
PCT/EP2019/069428 WO2020020751A1 (en) 2018-07-26 2019-07-18 Optimised dosage of diaminophenothiazines in populations

Publications (1)

Publication Number Publication Date
MX2021000894A true MX2021000894A (es) 2021-03-31

Family

ID=67587720

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000894A MX2021000894A (es) 2018-07-26 2019-07-18 Dosificacion optimizada de diaminofenotiazinas en poblaciones.
MX2023009856A MX2023009856A (es) 2018-07-26 2021-01-22 Dosificacion optimizada de diaminofenotiazinas en poblaciones.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023009856A MX2023009856A (es) 2018-07-26 2021-01-22 Dosificacion optimizada de diaminofenotiazinas en poblaciones.

Country Status (19)

Country Link
US (2) US20210236509A1 (es)
EP (3) EP3826639B1 (es)
JP (2) JP7465861B2 (es)
KR (1) KR20210038586A (es)
CN (1) CN112805008A (es)
AU (1) AU2019308873A1 (es)
BR (1) BR112021000802A2 (es)
CA (1) CA3106152A1 (es)
DK (1) DK3826639T3 (es)
ES (1) ES2989458T3 (es)
FI (1) FI3826639T3 (es)
HR (1) HRP20241360T1 (es)
IL (1) IL280361B2 (es)
MX (2) MX2021000894A (es)
PL (1) PL3826639T3 (es)
PT (1) PT3826639T (es)
SG (1) SG11202100333XA (es)
SI (1) SI3826639T1 (es)
WO (1) WO2020020751A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162313A (en) 2006-07-11 2017-05-31 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
CA3031578A1 (en) 2016-07-25 2018-02-01 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
JP2023524146A (ja) * 2020-05-05 2023-06-08 ウィスタ ラボラトリーズ リミテッド 低酸素血症の治療に使用されるメチルチオニニウム化合物
AU2021267670A1 (en) * 2020-05-05 2022-12-08 Wista Laboratories Ltd. Methylthioninium compounds for use in the treatment of COVID-19
GB202006659D0 (en) * 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
WO2024063700A1 (en) 2022-09-21 2024-03-28 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases
WO2024184146A1 (en) 2023-03-03 2024-09-12 Wista Laboratories Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
EP2001556B1 (en) 2006-03-29 2014-10-01 Wista Laboratories Ltd. Thioninium compounds and their use
SI2004155T1 (en) 2006-03-29 2018-05-31 Wista Laboratories Ltd. Protein aggregation inhibitors
CN101460472B (zh) 2006-03-29 2015-06-17 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪盐及其用途
CA2701075C (en) 2007-10-03 2019-02-12 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines.
WO2010078659A1 (en) 2009-01-12 2010-07-15 Foster Health Inc. Compositions and methods for nutritional prevention and treatment of alzheimer's-associated conditions
WO2010104375A1 (en) * 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
LT2673266T (lt) * 2011-02-11 2016-10-10 Wista Laboratories Ltd. Fenotiazino diaminio druskos ir jų panaudojimas
DK3258938T3 (da) * 2015-02-17 2021-02-01 Univ Arizona State Phenothiazinanaloger som mitokondrie terapeutiske midler
CA3031578A1 (en) * 2016-07-25 2018-02-01 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia

Also Published As

Publication number Publication date
PT3826639T (pt) 2024-10-09
IL280361A (en) 2021-03-01
SG11202100333XA (en) 2021-02-25
EP4385512A1 (en) 2024-06-19
JP2021532092A (ja) 2021-11-25
EP4364801A3 (en) 2024-07-10
US20210236509A1 (en) 2021-08-05
PL3826639T3 (pl) 2025-01-07
EP3826639B1 (en) 2024-08-21
US20230115931A1 (en) 2023-04-13
EP3826639A1 (en) 2021-06-02
HRP20241360T1 (hr) 2024-12-20
WO2020020751A1 (en) 2020-01-30
MX2023009856A (es) 2023-08-29
IL280361B1 (en) 2024-03-01
IL280361B2 (en) 2024-07-01
ES2989458T3 (es) 2024-11-26
JP2024096123A (ja) 2024-07-12
BR112021000802A2 (pt) 2021-04-13
FI3826639T3 (fi) 2024-10-30
SI3826639T1 (sl) 2025-01-31
DK3826639T3 (da) 2024-09-23
CN112805008A (zh) 2021-05-14
AU2019308873A1 (en) 2021-02-04
CA3106152A1 (en) 2020-01-30
KR20210038586A (ko) 2021-04-07
JP7465861B2 (ja) 2024-04-11
EP4364801A2 (en) 2024-05-08

Similar Documents

Publication Publication Date Title
MX2023009856A (es) Dosificacion optimizada de diaminofenotiazinas en poblaciones.
MX2021004431A (es) Procesos novedosos.
ZA202001057B (en) Inhibiting ubiquitin specific peptidase 30
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
EA200901373A1 (ru) Аминогетероциклические соединения
PH12013502262A1 (en) Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
PH12014501334A1 (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
PH12015502365B1 (en) Bace1 inhibitors
MX2019004280A (es) Organonitro-sulfoalquilo y compuestos relacionados y composiciones farmacéuticas para uso en medicina.
EA202090276A1 (ru) Фармацевтическая композиция для лечения анемии
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
UA117154C2 (uk) Антагоністи s1p3
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
EA201591021A1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
PH12017501668A1 (en) Bace1 inhibitors
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MX365292B (es) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas.
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.